RxDoctor Payments Data

Bruce Brent, MD

Cardiovascular Disease · San Francisco, CANPI 1093726879

Payments from drug & device makers

$17,949in general payments, 2019–2025

Across 290 payments — averaging $61.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$11K
  • Medtronic$2K
  • Amgen$729
  • Philips North America LLC$533
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$522
  • Heartflow, Inc.$473
  • plus $3K from 22 others

What the payments were for

  • Speaking & faculty fees$9,40052%
  • Grants$550%
  • Travel & lodging$6684%
  • Food & beverage$7,72243%
  • Education$1051%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,949 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$345,155
Medicare patients
902
Services billed
3,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban431$512,499
Repatha SureclickEvolocumab208$160,425
XareltoRivaroxaban115$148,004
JardianceEmpagliflozin72$72,449
EntrestoSacubitril/Valsartan48$63,765
Praluent PenAlirocumab62$57,732
Ezetimibe794$23,183
NexlizetBempedoic Acid/Ezetimibe18$14,508
FarxigaDapagliflozin Propanediol12$13,536
Ranolazine ErRanolazine77$11,618
Rosuvastatin Calcium640$11,519
Atorvastatin Calcium741$8,899
BrilintaTicagrelor11$8,427
Metoprolol Succinate526$7,707
Amlodipine Besylate725$5,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$408$512,499431 claims
Johnson & JohnsonXarelto$10,514$148,004115 claims
Boehringer IngelheimJardiance$268$72,44972 claims
NovartisEntresto$169$63,76548 claims
AstraZenecaFarxiga, Brilinta$113$21,96323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →